Cortecs signs exclusive licensing agreement with Inflazyme for ELISA and Rapid diagnostic products for diagnosing tuberculosis.
Business Wire › November 25, 1996
Linked as:
Extract
Cortecs signs exclusive licensing agreement with Inflazyme for ELISA and Rapid diagnostic products for diagnosing tuberculosis.
LONDON--(BUSINESS WIRE)--Nov. 25, 1996--Cortecs International ("Cortecs") (NASDAQ:DLVRY/LSE:COR/ASX:CRI) the UK based pharmaceutical company, has signed an exclusive worldwide agreement with a Canadian company, Inflazyme Pharmaceuticals Limited(a) ("Inflazyme") (NASDAQ-BB:IZYPF / VSE:IZP), for the development of an ELISA and also Rapid Point o...
See the full content of this document
Sponsored links
